Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:FRX
- CUSIP: 34583810
- Web: N/A
- Trailing P/E Ratio: N/A
- P/E Growth: 0
Frequently Asked Questions for Forest Laboratories (NYSE:FRX)
What is Forest Laboratories' stock symbol?
Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."
Who are some of Forest Laboratories' key competitors?
Some companies that are related to Forest Laboratories include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Zimmer Biomet Holdings (ZBH), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI) and Hikma Pharmaceuticals Plc (HIK).
How do I buy Forest Laboratories stock?
Shares of Forest Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Forest Laboratories' stock price today?
MarketBeat Community Rating for Forest Laboratories (NYSE FRX)MarketBeat's community ratings are surveys of what our community members think about Forest Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Forest Laboratories stock can currently be purchased for approximately $0.73.
Consensus Ratings for Forest Laboratories (NYSE:FRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Forest Laboratories (NYSE:FRX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Forest Laboratories (NYSE:FRX)Earnings History by Quarter for Forest Laboratories (NYSE FRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/29/2014||Q414||$0.45||$0.87||$959.00 million||$1.05 million||View||N/A|
|1/21/2014||Q314||$0.06||$0.27||$827.25 million||$846.80 million||View||N/A|
|7/23/2013||Q1 2014||$0.09||$0.28||$798.41 million||$796.90 million||View||N/A|
|4/23/2013||Q4 2013||$0.16||$0.17||$807.00 million||$783.20 million||View||N/A|
|1/15/2013||Q3 2013||($0.14)||($0.21)||$765.94 million||$678.00 million||View||N/A|
Earnings Estimates for Forest Laboratories (NYSE:FRX)
Current Year EPS Consensus Estimate: $-0.20 EPS
Dividend History for Forest Laboratories (NYSE:FRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Forest Laboratories (NYSE:FRX)Insider Trades by Quarter for Forest Laboratories (NYSE:FRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/27/2014||Howard Solomon||Director||Sell||250,000||$65.41||$16,352,500.00|| |
|1/23/2014||Howard Solomon||Director||Sell||250,000||$67.13||$16,782,500.00|| |
|1/22/2014||Jerome Lynch||SVP||Sell||135,625||$67.28||$9,124,850.00|| |
|8/26/2013||Lawrence Olanoff||Director||Sell||1,104||$42.96||$47,427.84|| |
|8/21/2013||Perier Francis, Jr.||CFO||Sell||12,000||$43.00||$516,000.00|| |
|9/4/2012||Carl C Icahn||Major Shareholder||Buy||86,848||$34.64||$3,008,414.72|| |
|8/29/2012||Carl C Icahn||Major Shareholder||Buy||331,406||$34.65||$11,483,217.90|| |
|8/24/2012||Carl C Icahn||Major Shareholder||Buy||1,343,837||$34.57||$46,456,445.09|| |
|8/21/2012||Carl C Icahn||Major Shareholder||Buy||1,962,011||$34.18||$67,061,535.98|| |
Headline Trends for Forest Laboratories (NYSE:FRX)
Latest Headlines for Forest Laboratories (NYSE:FRX)
Forest Laboratories (FRX) Chart for Wednesday, July, 26, 2017